CINGOLANI, LINDA
CINGOLANI, LINDA
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
2021 Barberio, B.; Cingolani, L.; Canova, C.; Barbieri, G.; Sablich, R.; Urbano, M. T.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Ferronato, A.; Buda, A.; Melatti, P.; Massimi, D.; Savarino, E. V.; Zingone, F.
A survey on nutritional knowledge in coeliac disease compared to inflammatory bowel diseases patients and healthy subjects
2020 Marsilio, I.; Savarino, E. V.; Barberio, B.; Lorenzon, G.; Maniero, D.; Cingolani, L.; D'Odorico, A.; D'Inca, R.; Zingone, F.
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
2021 Cingolani, L.; Barberio, B.; Zingone, F.; Ferronato, A.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Melatti, P.; Gubbiotti, A.; Massimi, D.; Casadei, C.; D'Inca, R.; Savarino, E. V.
Perception of the COVID-19 pandemic among patients with inflammatory bowel disease in the time of telemedicine: cross-sectional questionnaire study
2020 Zingone, F.; Siniscalchi, M.; Savarino, E. V.; Barberio, B.; Cingolani, L.; D'Inca, R.; Filippo, F. R. D.; Camera, S.; Ciacci, C.
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
2021 Massimi, D.; Barberio, B.; Bertani, L.; Costa, F.; Ferronato, A.; Facchin, S.; Cardin, R.; Cingolani, L.; Casadei, C.; D'Inca, R.; Zingone, F.; Savarino, E. V.